Find Faculty
Evren U Azeloglu, PhD
img_Evren U Azeloglu
PROFESSOR | Medicine, Nephrology
PROFESSOR | Pharmacological Sciences
212-241-8519
email
Research Topics
Biomechanics/Bioengineering, Biophysics, Cardiovascular, Cell Adhesion, Computational Biology, Cytoskeleton, Kidney, Mathematical Modeling of Biomedical Systems, Mathematical and Computational Biology, Nanotechnology, Signal Transduction, Stem Cells, Systems Biology, Systems Pharmacology, Tissue Engineering, Translational Research
Multi-Disciplinary Training Area
Artificial Intelligence and Emerging Technologies in Medicine [AIET], Development Regeneration and Stem Cells [DRS], Disease Mechanisms and Therapeutics (DMT)
Our main goal at the Systems Bioengineering Lab is to understand mechanobiological decision-making capabilities and to develop novel therapeutics for precision medicine. We employ multiscale experimental and computational techniques as well as microfabrication and tissue engineering methods to study cell signaling, biomechanics, tissue function and regeneration using human induced pluripotent stem cell-derived cardiovascular and renal model systems. We also use multi-platform omics technologies and network analyses for identification of key information processing hubs and regulatory motifs that can be used as therapeutic targets in drug development for complex diseases such as hypertension, diabetic nephropathy and heart failure. See Azeloglu Lab website for more details.

BE, Stony Brook University

MS, Stony Brook University

PhD, Columbia University

2015

NephCure Kidney International ASN Foundation Kidney Research Award

American Society of Nephrology

2010

Howard Hughes Medical Institute Fellowship

Life Science Research Foundation

2005

Stony Wold Herbert Fellowship

2004

Yuen-huo Hung & Chao-chin Huang Award (2009)

Columbia University

94
Publications

Selected Publications

LILRB3 genetic variation is associated with kidney transplant failure in African American recipients. Zeguo Sun, Zhengzi Yi, Chengguo Wei, Wenlin Wang, Tianyuan Ren, Paolo Cravedi, Fasika Tedla, Stephen C. Ward, Evren Azeloglu, Daniel R. Schrider, Yun Li, Atlas Khan, Francesca Zanoni, Jia Fu, Sumaria Ali, Shun Liu, Deguang Liang, Tong Liu, Hong Li, Caixia Xi, Thi Ha Vy, Gohar Mosoyan, Quan Sun, Ashwani Kumar, Zhongyang Zhang, Samira Farouk, Kirk Campell, Jordi Ochando, Kyung Lee, Steve Coca, Jenny Xiang, Patricia Connolly, Lorenzo Gallon, Philip J. O’Connell, Robert Colvin, Madhav C. Menon, Girish Nadkarni, John C. He, Monica Kraft, Xuejun Jiang, Xuewu Zhang, Krzysztof Kiryluk, Aravind Cherukuri, Fadi G. Lakkis, Weiguo Zhang, Shu Hsia Chen, Peter S. Heeger, Weijia Zhang. Nature Medicine

Correction to: LILRB3 genetic variation is associated with kidney transplant failure in African American recipients (Nature Medicine, (2025), 10.1038/s41591-025-03568-z). Zeguo Sun, Zhengzi Yi, Chengguo Wei, Wenlin Wang, Tianyuan Ren, Paolo Cravedi, Fasika Tedla, Stephen C. Ward, Evren Azeloglu, Daniel R. Schrider, Yun Li, Atlas Khan, Francesca Zanoni, Jia Fu, Sumaria Ali, Shun Liu, Deguang Liang, Tong Liu, Hong Li, Caixia Xi, Thi Ha Vy, Gohar Mosoyan, Quan Sun, Ashwani Kumar, Zhongyang Zhang, Samira Farouk, Kirk Campell, Jordi Ochando, Kyung Lee, Steve Coca, Jenny Xiang, Patricia Connolly, Lorenzo Gallon, Philip J. O’Connell, Robert Colvin, Madhav C. Menon, Girish Nadkarni, John C. He, Monica Kraft, Xuejun Jiang, Xuewu Zhang, Krzysztof Kiryluk, Aravind Cherukuri, Fadi G. Lakkis, Weiguo Zhang, Shu Hsia Chen, Peter S. Heeger, Weijia Zhang. Nature Medicine

Multiscale mapping of transcriptomic signatures for cardiotoxic drugs. Jens Hansen, Yuguang Xiong, Mustafa M. Siddiq, Priyanka Dhanan, Bin Hu, Bhavana Shewale, Arjun S. Yadaw, Gomathi Jayaraman, Rosa E. Tolentino, Yibang Chen, Pedro Martinez, Kristin G. Beaumont, Robert Sebra, Dusica Vidovic, Stephan C. Schürer, Joseph Goldfarb, James M. Gallo, Marc R. Birtwistle, Eric A. Sobie, Evren U. Azeloglu, Seth I. Berger, Angel Chan, Christoph Schaniel, Nicole C. Dubois, Ravi Iyengar. Nature Communications

View All Publications

Annenberg Building Floor 23 Room 02D

1468 Madison Ave

New York, NY 10029

212-241-8519

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Azeloglu during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Board Service

  • Flowpoint Medical Inc.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Orion Corporation

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Flowpoint Medical Inc.

Founder/Co-Founder/Partner

  • Flowpoint Medical Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.